Showcase your company news with guaranteed exposure both in print and online Join us as we continue our event series highlighting Pittsburgh's most important growth corridors… Don't miss our ...

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement ...